The first patients have been treated in WOLVERINE, a prospective feasibility trial of the Edison Histotripsy System for BPH. The first patients have been treated in the WOLVERINE study (NCT07214675), ...

The device will be available over the counter in the US, with anticipated availability beginning in April 2026. The FDA has granted 510(k) clearance to Elitone for Men, a non-invasive, at-home ...

In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response. Understanding how ...

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle. In this ...

Enolen's fast track designation by the FDA highlights its potential to address unmet needs in early-stage prostate cancer treatment. The implant technology aims to deliver high local drug ...

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...

AVZO-103 has received fast track designation for treating urothelial carcinoma, enabling accelerated development and review processes. The phase 1/2 trial will assess AVZO-103's safety, tolerability, ...

Cretostimogene grenadenorepvec shows a 24-month complete response rate of 41.8% in high-risk BCG-unresponsive patients with NMIBC, with 90% of 12-month responders maintaining CR. The BOND-003 trial ...

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and ...

Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...

A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

NCCN guideline-recommended treatments significantly reduce prostate cancer mortality compared to other causes, even in high-risk patients. The study involved 135,636 Swedish patients, with 46% ...